603998 方盛制药
已收盘 11-04 15:00:00
资讯
新帖
简况
股市必读:方盛制药新发布《方盛制药关于公司《药品生产许可证》变更的公告》
证券之星 · 04:43
股市必读:方盛制药新发布《方盛制药关于公司《药品生产许可证》变更的公告》
方盛制药(603998)披露中药创新药研发项目获得药物临床试验批准通知书,11月03日股价上涨1.2%
证券之星 · 11-03 19:25
方盛制药(603998)披露中药创新药研发项目获得药物临床试验批准通知书,11月03日股价上涨1.2%
方盛制药(603998.SH):双枣安神颗粒获药物临床试验批准
智通财经 · 11-02 19:18
方盛制药(603998.SH):双枣安神颗粒获药物临床试验批准
股市必读:方盛制药新发布《方盛制药关于2026年第三季度业绩说明会召开情况的公告》
证券之星 · 11-02 07:45
股市必读:方盛制药新发布《方盛制药关于2026年第三季度业绩说明会召开情况的公告》
股市必读:方盛制药新发布《方盛制药关于召开2026年第三季度业绩说明会的公告》
证券之星 · 10-26
股市必读:方盛制药新发布《方盛制药关于召开2026年第三季度业绩说明会的公告》
方盛制药最新公告:艾拉莫德片获得药品注册证书
证券之星 · 10-23
方盛制药最新公告:艾拉莫德片获得药品注册证书
方盛制药(603998)披露2026年第三季度业绩说明会公告,10月22日股价下跌4.12%
证券之星 · 10-22
方盛制药(603998)披露2026年第三季度业绩说明会公告,10月22日股价下跌4.12%
方盛制药(603998)10月21日主力资金净买入1206.03万元
证券之星 · 10-21
方盛制药(603998)10月21日主力资金净买入1206.03万元
方盛制药(603998)披露激励基金管理办法,10月15日股价下跌0.87%
证券之星 · 10-15
方盛制药(603998)披露激励基金管理办法,10月15日股价下跌0.87%
股市必读:方盛制药新发布《方盛制药2026年第二次临时股东会会议资料》
证券之星 · 10-12
股市必读:方盛制药新发布《方盛制药2026年第二次临时股东会会议资料》
方盛制药(603998)披露拟制定《激励基金管理办法》议案,10月09日股价上涨3.1%
证券之星 · 10-09
方盛制药(603998)披露拟制定《激励基金管理办法》议案,10月09日股价上涨3.1%
股市必读:方盛制药新发布《方盛制药第六届董事会2026年第六次临时会议决议公告》
证券之星 · 10-08
股市必读:方盛制药新发布《方盛制药第六届董事会2026年第六次临时会议决议公告》
股市必读:方盛制药新发布《方盛制药激励基金管理办法(待提交公司股东会审议)》
证券之星 · 09-30
股市必读:方盛制药新发布《方盛制药激励基金管理办法(待提交公司股东会审议)》
股市必读:方盛制药(603998)9月24日披露最新机构调研信息
证券之星 · 09-28
股市必读:方盛制药(603998)9月24日披露最新机构调研信息
方盛制药:9月23日接受机构调研,东方财富证券联合湖南基金业协会走进上市公司活动21人参与
证券之星 · 09-24
方盛制药:9月23日接受机构调研,东方财富证券联合湖南基金业协会走进上市公司活动21人参与
方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,9月22日股价下跌1.77%
证券之星 · 09-22
方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,9月22日股价下跌1.77%
每周股票复盘:方盛制药(603998)强力枇杷膏中选集采+拟推新股权激励
证券之星 · 09-20
每周股票复盘:方盛制药(603998)强力枇杷膏中选集采+拟推新股权激励
方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与
证券之星 · 09-14
方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与
方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%
证券之星 · 09-07
方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%
每周股票复盘:方盛制药(603998)H1净利增16.79%
证券之星 · 09-06
每周股票复盘:方盛制药(603998)H1净利增16.79%
加载更多
公司概况
公司名称:
湖南方盛制药股份有限公司
所属行业:
医药制造业
上市日期:
2014-12-05
主营业务:
湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是养血祛风止痛颗粒、玄七健骨片、小儿荆杏止咳颗粒、依折麦布片、藤黄健骨片、强力枇杷膏(蜜炼)、血塞通分散片、赖氨酸维B12颗粒、头孢克肟片、蒲地蓝消炎片、金英胶囊、龙血竭散、舒尔经胶囊。公司拥有国家火炬计划重点高新技术企业、国家企业技术中心、国家技术创新示范企业、国家博士后科研工作站等国家级创新资质,先后获评国家级守合同重信用企业、湖南省省长质量奖等多项重要荣誉。
发行价格:
14.85
{"stockData":{"symbol":"603998","market":"SH","secType":"STK","nameCN":"方盛制药","latestPrice":10.3,"timestamp":1793775600000,"preClose":10.1,"halted":0,"volume":13215300,"delay":0,"changeRate":0.0198,"floatShares":438999999,"shares":438999999,"eps":0.7443,"marketStatus":"已收盘","change":0.2,"latestTime":"11-04 15:00:00","open":10.1,"high":10.4,"low":10.08,"amount":136000000,"amplitude":0.0317,"askPrice":10.3,"askSize":539,"bidPrice":10.29,"bidSize":171,"shortable":0,"etf":0,"ttmEps":0.7443,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"adjPreClose":10.1,"symbolType":"stock","openAndCloseTimeList":[[1793755800000,1793763000000],[1793768400000,1793775600000]],"highLimit":11.11,"lowLimit":9.09,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":439081360,"isCdr":false,"pbRate":2.54,"roa":"--","peRate":13.838506,"roe":"16.33%","epsLYR":0.7,"committee":-0.005412,"marketValue":4523000000,"turnoverRate":0.0301,"status":0,"floatMarketCap":4523000000},"requestUrl":"/m/hq/s/603998","defaultTab":"news","newsList":[{"id":"2680222774","title":"股市必读:方盛制药新发布《方盛制药关于公司《药品生产许可证》变更的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680222774","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680222774?lang=zh_cn&edition=full","pubTime":"2026-11-04 04:43","pubTimestamp":1793738588,"startTime":"0","endTime":"0","summary":"公司公告汇总方盛制药关于公司《药品生产许可证》变更的公告公司完成《药品生产许可证》变更:长沙市麓松路789号生产范围取消“司来帕格”销售限制并新增生产线;望城经济开发区黄龙路368号新增“原料药”及相应生产线,原址核减“吲哚布芬”生产范围;该地址同时新增“原料药”,需通过GMP检查后方可生产上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400006546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680740038","title":"方盛制药(603998)披露中药创新药研发项目获得药物临床试验批准通知书,11月03日股价上涨1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680740038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680740038?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:25","pubTimestamp":1793705125,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘,方盛制药报收于10.1元,较前一交易日上涨1.2%,最新总市值为44.35亿元。该股当日开盘9.92元,最高10.2元,最低9.91元,成交额达1亿元,换手率为2.27%。方盛制药于近日披露《关于中药创新药研发项目获得药物临床试验批准通知书的公告》。公告显示,2026年10月30日,公司自主研发的中药1.1类创新药双枣安神颗粒获国家药品监督管理局核准签发的《药物临床试验批准通知书》,同意开展用于慢性失眠的临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300037946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680569067","title":"方盛制药(603998.SH):双枣安神颗粒获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680569067","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680569067?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:18","pubTimestamp":1793618316,"startTime":"0","endTime":"0","summary":"智通财经APP讯,方盛制药(603998.SH)发布公告,2026年10月30日,公司中药创新药研发项目双枣安神颗粒收到国家药品监督管理局核准签发的《药物临床试验批准通知书》。双枣安神颗粒为根据多年临床诊疗实践开发的临床有效经验方,用于治疗失眠症(肝肾阴虚证)。全方以补益肝肾、养血安神为核心,用于治疗失眠症(肝肾阴虚证)所致的心烦不寐、多梦易醒、心悸不安、腰膝酸软、头昏、耳鸣、健忘等。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603998","BMED","IBBQ","PSYK","BK0239","MDTX","IBBJ","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680783117","title":"股市必读:方盛制药新发布《方盛制药关于2026年第三季度业绩说明会召开情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2680783117","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680783117?lang=zh_cn&edition=full","pubTime":"2026-11-02 07:45","pubTimestamp":1793576718,"startTime":"0","endTime":"0","summary":"公司公告汇总:方盛制药于10月30日召开2026年第三季度业绩说明会,就归母净利润下滑、研发费用下降、分红安排及新产品市场覆盖等情况作出回应。公司公告汇总方盛制药关于2026年第三季度业绩说明会召开情况的公告湖南方盛制药股份有限公司于2026年10月30日召开2026年第三季度业绩说明会,公司董事长兼总经理周晓莉、独立董事袁雄、财务总监曹湘琦、董事会秘书何仕出席。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200002057.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678653132","title":"股市必读:方盛制药新发布《方盛制药关于召开2026年第三季度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2678653132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678653132?lang=zh_cn&edition=full","pubTime":"2026-10-26 08:11","pubTimestamp":1792973474,"startTime":"0","endTime":"0","summary":"公司公告汇总方盛制药关于召开2026年第三季度业绩说明会的公告湖南方盛制药股份有限公司将于2026年10月30日09:00-10:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会。方盛制药关于艾拉莫德片获得《药品注册证书》的公告2026年10月22日,湖南方盛制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》,艾拉莫德片获得药品批准文号并可进行生产。截至目前,国内已有30家企业取得该药品注册证书。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600002236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677928036","title":"方盛制药最新公告:艾拉莫德片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2677928036","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677928036?lang=zh_cn&edition=full","pubTime":"2026-10-23 18:07","pubTimestamp":1792750024,"startTime":"0","endTime":"0","summary":"方盛制药(603998.SH)公告称,公司收到药监局核准签发的《药品注册证书》,艾拉莫德片已获得药品批准文号并可进行生产。该药品主要用于活动性类风湿关节炎,注册分类为化学药品4类。截至公告日,该药品项目累计投入839.65万元。米内网数据显示,艾拉莫德片2025年销售额突破20亿元,同比增长27.09%。公司表示,此次获批有利于丰富产品品类,提升市场竞争力,但预计短期内不会对业绩产生较大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300033536.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677696193","title":"方盛制药(603998)披露2026年第三季度业绩说明会公告,10月22日股价下跌4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2677696193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677696193?lang=zh_cn&edition=full","pubTime":"2026-10-22 22:18","pubTimestamp":1792678699,"startTime":"0","endTime":"0","summary":"截至2026年10月22日收盘,方盛制药报收于10.0元,较前一交易日下跌4.12%,最新总市值为43.91亿元。该股当日开盘10.4元,最高10.46元,最低9.98元,成交额达1.15亿元,换手率为2.58%。近日,方盛制药发布《关于召开2026年第三季度业绩说明会的公告》。公告显示,公司将于2026年10月30日09:00-10:00通过上证路演中心网络互动方式召开2026年第三季度业绩说明会,介绍公司经营成果和财务状况。投资者可于2026年10月23日至10月29日16:00前通过上证路演中心网站或公司邮箱提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200042759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0060","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677625314","title":"方盛制药(603998)10月21日主力资金净买入1206.03万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677625314","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677625314?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:27","pubTimestamp":1792567630,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2026年10月21日收盘,方盛制药报收于10.43元,下跌2.16%,换手率2.15%,成交量9.45万手,成交额9966.03万元。方盛制药主营业务:从事药品的研发、生产与销售,主要品类有:心脑血管用药、骨伤科药、呼吸系统用药、儿科药、妇科药和抗感染药等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100021236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675535529","title":"方盛制药(603998)披露激励基金管理办法,10月15日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2675535529","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675535529?lang=zh_cn&edition=full","pubTime":"2026-10-15 22:51","pubTimestamp":1792075871,"startTime":"0","endTime":"0","summary":"截至2026年10月15日收盘,方盛制药报收于10.26元,较前一交易日下跌0.87%,最新总市值为45.05亿元。该股当日开盘10.21元,最高10.44元,最低10.18元,成交额达7994.22万元,换手率为1.76%。近日,方盛制药发布《激励基金管理办法》公告。该办法已经公司2026年第二次临时股东会审议通过,自2026年度起执行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101500039995.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674484531","title":"股市必读:方盛制药新发布《方盛制药2026年第二次临时股东会会议资料》","url":"https://stock-news.laohu8.com/highlight/detail?id=2674484531","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674484531?lang=zh_cn&edition=full","pubTime":"2026-10-12 01:55","pubTimestamp":1791741312,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘,方盛制药报收于10.63元,上涨3.1%,换手率3.57%,成交量15.68万手,成交额1.65亿元。公司公告汇总:方盛制药将于10月15日召开2026年第二次临时股东会,审议《关于制定〈方盛制药激励基金管理办法〉的议案》。该办法旨在建立健全公司激励约束机制,调动核心管理层及关键人员积极性,推动股东利益、公司利益与个人利益的协调统一。议案已于2026年第六届董事会第六次临时会议审议通过,并于2026年9月30日在上交所网站披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200000617.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674605850","title":"方盛制药(603998)披露拟制定《激励基金管理办法》议案,10月09日股价上涨3.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674605850","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674605850?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:20","pubTimestamp":1791555627,"startTime":"0","endTime":"0","summary":"截至2026年10月9日收盘,方盛制药报收于10.63元,较前一交易日上涨3.1%,最新总市值为46.67亿元。该股当日开盘10.24元,最高10.68元,最低10.22元,成交额达1.65亿元,换手率为3.57%。近日,方盛制药披露2026年第二次临时股东会会议资料,公司将于2026年10月15日召开临时股东大会,审议《关于制定<方盛制药激励基金管理办法>的议案》。议案已于2026年第六届董事会第六次临时会议审议通过,并于2026年9月30日在上交所网站披露。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673129020","title":"股市必读:方盛制药新发布《方盛制药第六届董事会2026年第六次临时会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2673129020","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673129020?lang=zh_cn&edition=full","pubTime":"2026-10-08 02:11","pubTimestamp":1791396671,"startTime":"0","endTime":"0","summary":"公司公告汇总方盛制药第六届董事会2026年第六次临时会议决议公告湖南方盛制药股份有限公司第六届董事会2026年第六次临时会议于2026年9月29日召开,审议通过《关于制定〈方盛制药激励基金管理办法〉的议案》和《关于提请召开公司2026年第二次临时股东会的议案》,均获全票通过;其中激励基金管理办法尚需提交股东会审议;公司定于2026年10月15日召开临时股东会。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671024170","title":"股市必读:方盛制药新发布《方盛制药激励基金管理办法(待提交公司股东会审议)》","url":"https://stock-news.laohu8.com/highlight/detail?id=2671024170","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671024170?lang=zh_cn&edition=full","pubTime":"2026-09-30 02:27","pubTimestamp":1790706430,"startTime":"0","endTime":"0","summary":"截至2026年9月29日收盘,方盛制药报收于10.26元,下跌0.97%,换手率1.6%,成交量7.03万手,成交额7247.05万元。公司公告汇总:方盛制药拟实施《激励基金管理办法》,待提交股东大会审议,激励前提为扣非净利润同比增长超10%且为正、审计意见为标准无保留意见。激励对象需满足个人绩效考核合格等要求,由董事会薪酬与考核委员会审核,董事会审议决定计提与分配方案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000002577.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409481","title":"股市必读:方盛制药(603998)9月24日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409481?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:00","pubTimestamp":1790532046,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘,方盛制药报收于10.29元,下跌1.53%,换手率1.66%,成交量7.28万手,成交额7548.01万元。当日关注点交易信息汇总:9月24日主力资金净流出746.79万元,占总成交额9.89%。机构调研要点:控股子公司暨大基因正推进IMMH024化药1类创新药IND前系统研究,并与香港大学开展抗体融合蛋白药物合作。公司已制定《核心人才长效激励制度》,2022年限制性股票激励计划已实施完毕,新一期股权激励计划处于持续规划论证阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","603998","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669496508","title":"方盛制药:9月23日接受机构调研,东方财富证券联合湖南基金业协会走进上市公司活动21人参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2669496508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669496508?lang=zh_cn&edition=full","pubTime":"2026-09-24 22:04","pubTimestamp":1790258698,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月24日方盛制药发布公告称公司于2026年9月23日接受机构调研,东方财富证券联合湖南基金业协会走进上市公司活动21人参与。2026年6月,香港方盛堂已取得香港卫生署颁发的《中成药制造商牌照》,正式成为香港持牌中成药制造商。此外,公司成立专门的国际业务部,积极关注国际市场以及优质项目。公司将稳步推进各项生产研发销售工作,创造更好业绩报全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400040682.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","300059","BK0188","LU2097828631.EUR","LU2148510915.USD","LU2580892789.USD","LU1831875114.USD","LU1997244956.HKD","LU2097828805.USD","LU2097828557.USD","LU1997245094.SGD","LU0326950275.SGD","LU2495084118.USD","LU2097828714.EUR","LU2097828474.EUR","BK0055","BK0095","BK0201","LU1997245177.USD","603998","BK0077","LU1064131003.USD","LU2580892862.HKD","LU2289578879.USD","BK0028","BK0239","161027","BK0276","LU1981816686.USD","SG9999014674.SGD","LU1064130708.USD","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669412854","title":"方盛制药(603998)披露转让控股子公司部分股权暨引进战略投资者进展公告,9月22日股价下跌1.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669412854","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669412854?lang=zh_cn&edition=full","pubTime":"2026-09-22 22:26","pubTimestamp":1790087177,"startTime":"0","endTime":"0","summary":"近日,湖南方盛制药股份有限公司发布关于转让控股子公司部分股权暨引进战略投资者的进展公告。截至公告日,佰骏医疗已累计偿还12,300万元,尚余4,346.39万元未还。因资金计划调整,佰骏医疗未能在2026年9月21日足额还款,仅于9月21日、22日各偿还100万元,合计200万元,剩余400万元预计于10月底前偿还。公司提示仍存在佰骏医疗无法按时足额还款的风险,将持续关注并保留追责权利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200041894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668590601","title":"每周股票复盘:方盛制药(603998)强力枇杷膏中选集采+拟推新股权激励","url":"https://stock-news.laohu8.com/highlight/detail?id=2668590601","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668590601?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:40","pubTimestamp":1789839623,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘,方盛制药报收于10.39元,较上周的10.17元上涨2.16%。本周,方盛制药9月14日盘中最高价报10.55元。本周关注点来自机构调研要点:强力枇杷膏(蜜炼)中选全国中成药采购联盟集中带量采购,有望提升市场占有率。小儿荆杏止咳颗粒已向药监局提出成人适用症相关事项补充申请并收到《受理通知书》,强力枇杷膏(蜜炼)中选全国中成药采购联盟集中带量采购,有望提高市场占有率,提升公司的品牌影响力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000346.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657349","title":"方盛制药:9月10日接受机构调研,华源证券、南方基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657349","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667657349?lang=zh_cn&edition=full","pubTime":"2026-09-14 18:08","pubTimestamp":1789380486,"startTime":"0","endTime":"0","summary":"证券之星消息,2026年9月14日方盛制药发布公告称公司于2026年9月10日接受机构调研,华源证券、南方基金、浩友投资参与。随着集采药品“三进”政策持续推进,产品院外渠道覆盖有望进一步扩大,为存量品种持续释放市场潜力创造有利条件。2026年6月,香港方盛堂已取得香港卫生署颁发的《中成药制造商牌照》,正式成为香港持牌中成药制造商。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091400024640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603998","BK0239","161027","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665311705","title":"方盛制药(603998)披露2026年半年度权益分派实施公告,9月7日股价上涨1.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665311705","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665311705?lang=zh_cn&edition=full","pubTime":"2026-09-07 17:45","pubTimestamp":1788774310,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘,方盛制药报收于10.92元,较前一交易日上涨1.11%,最新总市值为47.95亿元。该股当日开盘10.75元,最高11.0元,最低10.75元,成交额达1.03亿元,换手率为2.15%。方盛制药于近日披露《2026年半年度权益分派实施公告》。股权登记日为2026年9月10日,除权(息)日与现金红利发放日均为2026年9月11日。分配对象为截至股权登记日在中国证券登记结算有限责任公司上海分公司登记在册的全体股东。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700023042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","603998"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365958","title":"每周股票复盘:方盛制药(603998)H1净利增16.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365958","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365958?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:51","pubTimestamp":1788630670,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘,方盛制药报收于10.8元,较上周的10.5元上涨2.86%。本周,方盛制药8月31日盘中最高价报11.39元。9月4日盘中最低价报10.74元。方盛制药当前最新总市值47.42亿元,在中药板块市值排名44/66,在两市A股市值排名3332/5214。主营业务方面,心脑血管用药收入同比增长50.01%,骨骼肌肉系统用药收入同比增长10.80%。公司2026年半年度拟每股派现0.20元(含税),分红金额预计达87,816,272元,占归母净利润的44.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","603998","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793781280456,"stockEarnings":[{"period":"1week","weight":-0.0279},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0893},{"period":"6month","weight":-0.0524},{"period":"1year","weight":-0.1244},{"period":"ytd","weight":-0.0582}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0609},{"period":"3month","weight":-0.0697},{"period":"6month","weight":-0.1368},{"period":"1year","weight":-0.0926},{"period":"ytd","weight":-0.0909}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南方盛制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27432人(较上一季度增加15.96%)","perCapita":"16006股","listingDate":"2014-12-05","address":"湖南省长沙市岳麓区高新区麓松路789号","registeredCapital":"43908万元","survey":" 湖南方盛制药股份有限公司的主营业务是药品的研发、生产与销售。公司的主要产品是养血祛风止痛颗粒、玄七健骨片、小儿荆杏止咳颗粒、依折麦布片、藤黄健骨片、强力枇杷膏(蜜炼)、血塞通分散片、赖氨酸维B12颗粒、头孢克肟片、蒲地蓝消炎片、金英胶囊、龙血竭散、舒尔经胶囊。公司拥有国家火炬计划重点高新技术企业、国家企业技术中心、国家技术创新示范企业、国家博士后科研工作站等国家级创新资质,先后获评国家级守合同重信用企业、湖南省省长质量奖等多项重要荣誉。","listedPrice":14.85},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"方盛制药,603998,方盛制药股票,方盛制药股票老虎,方盛制药股票老虎国际,方盛制药行情,方盛制药股票行情,方盛制药股价,方盛制药股市,方盛制药股票价格,方盛制药股票交易,方盛制药股票购买,方盛制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"方盛制药(603998)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供方盛制药(603998)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}